行情

NVTA

NVTA

Invitae
NYSE

实时行情|Nasdaq Last Sale

33.47
-0.83
-2.42%
盘后: 33.90 +0.43 +1.28% 19:53 07/10 EDT
开盘
33.96
昨收
34.30
最高
34.66
最低
32.94
成交量
146.33万
成交额
--
52周最高
35.33
52周最低
7.42
市值
41.84亿
市盈率(TTM)
-10.6684
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVTA价格均价为29.06,最高价位35.00,最低价为25.00。

EPS

NVTA 新闻

更多
How Fast Is Too Fast Where Fashion Is Concerned?
Bloomberg · 3天前
XBI: Not Everybody Can Be A Hero
Seeking Alpha - Article · 3天前
PRESS DIGEST-British Business - July 8
Reuters · 3天前
PRESS DIGEST- Financial Times - July 8
Reuters · 3天前
Hedge Funds Aren’t Crazy About InVitae Corporation (NVTA)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 5天前
European stocks open higher after Asia bounce
European shares opened higher on Friday after upbeat China data fuelled a bounce in Asian markets, but another record surge in U.S. coronavirus cases checked overall investor optimism. The pan-European STOXX 600 index rose 0.2% to hover near its strongest lev
Reuters · 07/03 07:28
Here's Why Invitae (NVTA) is a Great Momentum Stock to Buy
Does Invitae (NVTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 07/02 16:00
INVITAE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Invitae Corporation - NVTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Invitae Corporation (NYSE: NVTA) ("the Company") with ArcherDX in a stock-for-stock transaction. KSF is
Business Wire · 07/01 22:48

所属板块

生物技术和医学研究
-0.39%
制药与医学研究
-0.32%

热门股票

代码
价格
涨跌幅

NVTA 简况

Invitae Corporation(简称Invitae)利用整合的实验室过程、软件工具和信息能力组合处理含脱氧核糖核酸(DNA)的样品,分析患者特异性遗传变异信息,并为临床医生及其患者生成测试报告。该公司的实验室位于加利福尼亚州的旧金山。该公司的产品是一种包括超过600种基因可用于多种适应症的检测。该测试包括与遗传性癌症、神经系统功能障碍、心血管功能障碍和其他遗传性病症相关的多种基因。该公司提供在遗传癌症、心脏病学、神经肌肉、儿科和罕见疾病中超过120种适应症的研究组。该公司提供基因全长测序和基因敲除/复制分析作为其所有测试的标准。该公司开发帮助医疗保健专业人员定制测试和接收申请测试结果的产品与服务。
展开

微牛提供InVitae Corp(NYSE-NVTA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVTA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NVTA股票基本功能。